BriaCell’s Expanding Horizon: Beyond Breast Cancer

BriaCell’s current research and development efforts are focused on giving hope to patients living with metastatic breast cancer. The company is currently conducting a Phase 3 clinical study of its lead candidate Bria-IMT in combination with an immune check point inhibitor (listed on ClinicalTrials.gov as NCT06072612) in metastatic breast cancer, with Fast Track status from the FDA. However, breast cancer patients aren’t the only ones who may benefit from BriaCell’s research. Our long-term goal is to extend our treatments to other solid tumors, including prostate cancer, lung cancer, and melanoma.

BriaCell is currently conducting a Phase 1/2 study of its personalized immunotherapy, Bria-OTS™/Bria-OTS+™, (listed on ClinicalTrials.gov as NCT06471673) in metastatic breast cancer. Additionally, BriaCell has been developing multiple product candidates for various cancer indications. These products have yet to enter clinic for clinical studies, and Bria-PROS+™, which is currently in development but uses a similar personalized immunotherapy method to our existing drugs and is expected to be well-tolerated and effective.

One Platform Technology, Many Cancers

Bria-OTS+™ is an off-the-shelf, Human Leukocyte Antigen (HLA) matched immunotherapy for cancer. It activates the immune system through various mechanisms including activating T-cells and NK cells to target tumors. BriaCell is currently evaluating Bria-BRES™/Bria-BRES+™ in a Phase 1/2 study for breast cancer (listed on ClinicalTrials.gov as NCT06471673), and is developing Bria-PROS+™ for prostate cancer, Bria-LUNG+™ for lung cancer, and Bria-MEL+™ for melanoma.

The Strategic “Bucket Trial”

To accelerate the development of cancer-fighting drugs, BriaCell has been authorized by the FDA to conduct a Phase 1/2 “bucket trial” — testing BriaCell’s personalized immunotherapies for different types of cancers.

The Expanding Target List

Building on our initial success with metastatic breast cancer, we’re looking to apply HLA-matched therapy to other cancers.

Prostate Cancer

Prostate cancer kills over 35,000 patients every year in the US alone. Bria-PROS+™ is a cellular immunotherapy designed specifically with prostate cancer in mind. The immunotherapy is currently being prepared for Phase 1/2 testing.

Lung Cancer

According to American Cancer Society, lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women in the United States (not counting skin cancer). The same HLA-matched therapy that makes Bria-OTS™ so promising for breast cancer could help to activate the immune system against tumors in the lungs, too. We believe our Bria-LUNG+™ can offer an effective treatment with an excellent tolerability profile in lung cancer. Lung cancer is planned to be included in the bucket trial in BriaCell’s Phase 1/2 study of Bria-OTS™(listed on ClinicalTrials.gov as NCT06471673).

Melanoma

Melanoma is an aggressive form of skin cancer, and we believe our Bria-MEL+™ can offer an effective treatment with an excellent tolerability profile in melanoma. To that end, melanoma is one of the solid tumor cancers that is planned to be included in the bucket trial in BriaCell’s Phase 1/2 study of Bria-OTS™( listed on ClinicalTrials.gov as NCT06471673).

Personalized Immunotherapy for Cancer Patients

BriaCell’s drugs use Human Leukocyte Antigen (HLA) matching to provide personalized immunotherapy for cancer, but is also off-the-shelf, reducing cost and increasing convenience. While our primary focus so far has been on metastatic breast cancer, we believe the same method has the potential to give hope to patients with prostate cancer, lung cancer, melanoma, and many other types of cancer.

Our mission is to transform cancer care by offering an effective, well-tolerated treatment that can be used when early treatments fail.

See our full clinical pipeline, or explore our BriaCell’s technology pages to learn more about BriaCell’s novel technology.

Stay informed on the progress of our clinical trials: Read our latest corporate news.